"Obesity was a major risk factor for poor outcomes with COVIDbut I would actually go further that obesity is a major risk factor for poor outcomes basically in all walks of life," Buse noted
Retatrutide, a newer triple agonist targeting GIP, GLP-1, and glucagon receptors, has a half-life of approximately six days
The company has been in business for nine years, having started on February 2, 2017, according to their Better Business Bureau profile
Weight loss medication is not recommended to those without a prescription or guidance from a medical professional
Dosing should be set by a prescribing provider
The first arena has focused on the induction of fetal hemoglobin (HbF) to alleviate disease severity